Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
A phase II, multi-center, open-label, single-arm, non-randomized study to evaluate the
efficacy, safety and tolerability of IMP4297 capsules in subjects with germline and/or
systemic BRCA1/2 mutated advanced ovarian cancer in china